As semaglutide and tirzepatide seek to expand their approved indications, e.g., potentially adding heart failure, chronic kidney disease or MASH, following several successful phase 3 trial readouts in 2023 and 2024, more pathways open up to Medicare reimbursement of AOMs within existing rules
Follow the recommended application guidance
Longer breaks might require restarting again at a lower dose, and we can help you get back on track safely
You dont need to follow a one-size-fits-all approach
Cold injections sting more and can cause more localized irritation
Injectable healing protocol: 23 mg daily (upper end of range), systemic injection - not into the wound itself - daily until the wound resolves, plus 12 weeks maintenance Topical healing protocol: 2 %4 % in a wound-appropriate vehicle applied 23 times daily to wound margins (never into an open, actively bleeding wound) under clinician supervision Stacking: GHK-Cu pairs exceptionally well with BPC-157 and TB-500 - the so-called GLOW stack - for complex healing cases
